EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash
Article content
Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful improvement in disease activity at Week 16
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Lupus rash can lead to physical discomfort and emotional distress, highlighting the need for effective treatments to manage its signs and symptoms
Article content
Article content
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demonstrating clinically meaningful reduction in disease activity in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active lupus rash. The findings are from Cohort A of the Phase 2 WILLOW study ( NCT05162586). Results will be presented at the 16 th International Congress on Systemic Lupus Erythematosus (LUPUS 2025), taking place May 21-24 in Toronto.
Article content
WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus standard of care (SoC) over 24 weeks. The study features a unique design across two lupus cohorts, including both patients with active SLE and CLE. Cohort A focused on patients with CLE or SLE with active lupus rash and evaluated organ-specific disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score, a well-defined endpoint in CLE studies that measures different aspects of mucocutaneous manifestations. Cohort B was designed to evaluate the effect of enpatoran on systemic disease activity of SLE patients with the BICLA response endpoint.
Article content
Cohort A met its primary endpoint, demonstrating a dose-response relationship and showing a clinically meaningful improvement in CLASI-A scores at Week 16 (p = 0.0002). Additionally, at Week 24 up to 91.3% of patients receiving enpatoran achieved a CLASI-50 response (≥50% improvement from baseline), and up to 60.9% achieved a CLASI-70 response (≥70% improvement), compared with 38.5% and 11.5%, respectively, in the placebo group. In this cohort, enpatoran was well-tolerated, and exhibited a manageable safety profile consistent with previous studies, with no new safety signals identified.
Article content
'Lupus can make navigating everyday life difficult. The skin manifestation, known as lupus rash, often comes with persistent itching, which can lead to scarring and hair loss. This can significantly impact the physical, emotional and social well-being of those living with lupus, underscoring the urgent need for effective treatments,' said Jan Klatt, Head of Development Unit Neurology & Immunology for the Healthcare business of Merck KGaA, Darmstadt, Germany. 'We are encouraged by the WILLOW results, where we observed clinically meaningful efficacy with a favorable safety profile in people living with lupus rash. Based on these results, discussions with health authorities on a global Phase 3 program with enpatoran are underway.'
Article content
In addition, and confirming the biological activity, treatment with enpatoran in Cohort A also led to a rapid reduction in interferon gene signature scores beginning at Week 2, which was maintained to Week 24, confirming the involvement of the TLR7/8 pathway in interferon activation in CLE. Overall, evidence from the WILLOW study supports the continued development of enpatoran as a treatment for autoimmune diseases like lupus.
Article content
On Cohort B of the WILLOW study, promising efficacy results were observed in prespecified subpopulations, even though the primary endpoint of dose response was not met. The full readout from this cohort will be presented at the European Alliance of Associations for Rheumatology Congress (EULAR 2025).
Article content
Principal investigator Prof. Eric Morand of Monash University and Monash Health, said, 'These new findings offer promising evidence that, with enpatoran, we may be able to advance outcomes, which remain suboptimal for most patients. The data from the WILLOW study further our understanding of TLR7/8 inhibition in SLE and CLE, which is a novel mechanism of action that may offer new hope for patients.'
Article content
Toll-like receptors (TLR)7 and TLR8 play a relevant role in lupus pathogenesis and are associated with severe manifestations of the disease. By inhibiting these key disease drivers, enpatoran's unique proposed mechanism of action aims to enhance therapeutic efficacy while preserving the body's immune response, potentially overcoming limitations of existing lupus therapies.
Article content
About Enpatoran
Article content
Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting TLR7/8 activation, enpatoran may help reduce pro-inflammatory cytokines and autoantibody production, potentially addressing underlying mechanisms of chronic inflammation and disease progression in lupus. With its novel proposed mechanism of action and oral administration, enpatoran has the potential to be a first-in-class treatment for patients across lupus conditions. Enpatoran is currently under clinical investigation and is not approved for any use anywhere in the world.
Article content
WILLOW ( NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). The study incorporates a basket design, including two cohorts – Cohort A including patients with CLE or SLE with active lupus rash and Cohort B including patients with active SLE. The WILLOW study aims to advance the understanding of enpatoran's therapeutic potential and to help address significant unmet needs in lupus treatment.
Article content
About Lupus Erythematosus
Article content
Lupus erythematosus is a chronic autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys and other organs. It occurs when the immune system mistakenly attacks healthy tissues, leading to inflammation, pain and potential organ damage. There are multiple types of lupus, with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) being two primary forms. Symptoms can range from mild to life-threatening, often including fatigue, joint pain, rashes and organ involvement. Lupus disproportionately impacts women and people of color, and despite available treatments, many patients experience unmet needs due to limited efficacy or side effects.
Article content
EMD Serono in Neurology and Immunology
Article content
EMD Serono has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company's current MS portfolio includes two products for the treatment of relapsing MS – Rebif ® (interferon beta-1a) and MAVENCLAD ® (cladribine) tablets. EMD Serono aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to EMD Serono's commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG).
Article content
About EMD Serono, Inc.
Article content
EMD Serono – the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada – aspires to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. The business is imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. EMD Serono's global roots go back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, the business has approximately 1,050 employees around the country with commercial, clinical and research operations in Massachusetts. www.emdserono.com.
Article content
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries.
Article content
The company holds the global rights to the name and trademark 'Merck' internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Article content
Article content
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
14 minutes ago
- CTV News
Coal mines on Alberta's eastern slopes could push fishery ‘beyond recovery': study
Grassy Mountain, peak to left, and the Grassy Mountain Coal Project are seen north of Blairmore, Alta., Thursday, June 6, 2024. (THE CANADIAN PRESS/Jeff McIntosh) Old coal mines on the eastern slopes of the Alberta Rockies are leaching chemicals that are poisoning the fish downstream, says a new study by Alberta government scientists. It also suggests any new coal developments could result in 'population collapse' of fish species in a nearby lake. The findings were made in a provincial government study posted online May 27. The paper is awaiting peer review. The scientists who authored it were not made available to speak to reporters. The other authors not employed by the province did not respond to requests for comment. Alberta has responded to the study with an advisory saying people should consider 'limiting consumption' of three fish species drawn from Crowsnest Lake, a fishing spot downstream from the coal mines. Those species were found to have dangerously high levels of selenium, a mineral found in coal-rich deposits, in their body tissue. The authors write the study shows that 'biological impacts of (mountaintop removal) coal mining can persist long after mining operations end.' They suggest that 'any further coal mine development may well push the Crowsnest fishery beyond sustainability.' The study comes after the Alberta Energy Regulator, or AER, granted an Australia-based coal company permission to start a controversial coal exploration on the eastern slopes. The project was initially rejected in 2021 when a panel ruled the likely environmental effects on fish and water quality outweighed potential economic benefits. But the regulator said last month it's possible there will be runoff from the nearby pit lake that Northback Holding Corp. is using. It ultimately concluded the project won't have any effect on the water quality downstream. The AER said that 'out of an abundance of caution,' Northback will have to comply with a directive for managing drilling waste in response to concerns over selenium. The new study measured selenium levels in fish from Crowsnest Lake, which is fed by creeks connected to Tent Mountain and Grassy Mountain – both former coal mine sites. Alberta has a fish tissue selenium guideline of four micrograms per gram. The authors write that every single fish sample analyzed exceeded this value. Average selenium concentrations were highest in Brown Trout, coming in at 18 micrograms per gram. The authors write that the selenium levels could lead to 'behavioural changes, physical symptoms ... respiratory issues, reproductive issues and ultimately population collapse.' Accumulating fluid in body tissue or fin and tail damage are among other side effects. Most people are exposed to healthy levels of selenium through grains and flours, but Health Canada says elevated consumption can lead to hair loss, decreased cognitive function and gastrointestinal disorders. The high selenium concentrations can only be explained by 'the incorporation of legacy coal mine pollution,' the authors write. The study goes on to say selenium levels in fish in Crowsnest Lake are similar to those found in water bodies near Fernie, B.C., that resulted in Teck Mining Company, which owned and operated a nearby mine, being forced in 2021 by B.C. provincial court to pay a $60 million fine – the largest fine ever imposed under the Fisheries Act. Fish populations in those mining-impacted streams were found in 2011 to have an average selenium concentration of 7.6 micrograms per gram. Nine years later, the adult westslope cutthroat population had suffered a 93 per cent decline, the study says. The authors conclude that factors including the emergence of Whirling Disease, drought conditions, high fishing activity -- and now high selenium levels in fish -- make the Crowsnest Lake and River 'an especially vulnerable system.' 'Any new development of coal mining along the eastern slopes may well push the Crowsnest fishery beyond recovery,' they write. Colin Cooke, one of the authors, published a 2024 study that found a former coal mine in the Crowsnest River watershed was releasing selenium to fish at rates more than dozens of times higher than federal and provincial guidelines. Cooke is a senior aquatic scientist with the Alberta government, according to LinkedIn. Peter Doyle, CEO of Evolve Power Ltd., formerly Montem Resources Ltd., which previously sought to restart an old mine on Tent Mountain, said in an email that the company is complying with terms set out by the AER. 'As reflected in other work by the author, there are numerous contributors to water quality in the Crowsnest River valley, not related to Tent Mountain, including changes in upstream conditions, changes in weathering rates and other anthropogenic changes in the watershed,' Doyle wrote, referring to Cooke's 2024 study. That report notes those factors, among others, could be contributing to contaminant levels and concluded that coal mining activities in the Crowsnest River watershed 'have been impacting ecosystems downstream for decades.' Northback, in an email, wrote that Crowsnest Lake is unrelated to its Grassy Mountain project. 'However, with our own project, Northback is committed to adhering to the highest environmental standards and ensuring a safe water supply.' Ryan Fournier, press secretary for Alberta's environment ministry, deferred questions about monitoring and enforcement to the AER. He said the province is funding a series of studies and submitting them to peer-reviewed academic journals as the province revises its coal policy. He also said the authors were not available to speak to media because they 'are not trained spokespeople.' The AER told The Canadian Press that it has directed Evolve Power, the Tent Mountain owner, to submit a 'selenium management plan proposal' that targets reductions in selenium in mine-affected water. Evolve was to submit that plan by July 31 of last year, but the AER said it granted the company an extension to March 31, 2026. The energy regulator also said that while selenium levels are elevated, 'there is no evidence of non-compliance on monitoring or selenium management requirements at this time.' The province announced in December it would allow coal mining to take place in Alberta under certain conditions. However, it exempted Northback and Evolve Power's projects from those rules because they were considered 'advanced.' Fisheries and Oceans Canada said in a statement that it doesn't comment on provincial permitting decisions and it hasn't been asked to review the local impacts to wildlife in the area. This report by The Canadian Press was first published June 6, 2025. Matthew Scace, The Canadian Press
CTV News
37 minutes ago
- CTV News
Canadian, European space agencies reaffirm relations amid political, economic anxiety
Canada Space Agency president Lisa Campbell, left, and director general of the European Space Agency (ESA) Josef Aschbacher display their signed reaffirmations of the Canada-European Space Agency Cooperation Agreement in Longueuil, Que., on Friday, June 6, 2025. THE CANADIAN PRESS/Christinne Muschi LONGUEUIL — The Canadian and European space agencies say economic and geopolitical turmoil are forcing them to work closer together. Leaders at both organizations signed a joint statement today at Canadian Space Agency headquarters south of Montreal reaffirming their co-operation. Josef Aschbacher, director general of the European Space Agency, says space programs are having to contend with economic uncertainty and global conflicts. His visit comes as the United States is pressuring NATO members to increase their spending on defence — a sector of the economy that is tightly linked to space. As well, Aschbacher says the United States' space agency — NASA — could be facing deep budget cuts. Canadian Space Agency president Lisa Campbell says that in uncertain times it's important to reaffirm relationships with like-minded allies. This report by The Canadian Press was first published June 6, 2025.
CBC
41 minutes ago
- CBC
Nova Scotia Health approaching goal of reduced surgical waitlist
The interim head of the provincial health authority says enough progress has been made to reduce the surgical backlog in Nova Scotia that she's not looking over her shoulder. In December of 2022, Karen Oldfield vowed before the legislature's health committee — first asking for a Bible to swear upon before crossing her heart in the absence of the Good Book — that the backlog would be reduced by 10,000 people by mid-2025. At the time, the list stood at about 22,000 people. Such a decrease would bring the province in line with national benchmarks for surgical waitlists. "I'm not going to hell," Oldfield joked with reporters Friday following an appearance on a panel at a Halifax Chamber of Commerce luncheon to discuss innovation in health care. "We are 1,500 surgeries away from what we would consider to be an appropriate [waitlist]. With any luck, we will hit that this year." Waitlist dropping year over year Statistics released by Nova Scotia Health show the province's waitlist as of April 1 of this year was 15,769 people. That's down from 17,369 people the same time the year before, and 19,917 people as of April 1, 2023. The procedures with the largest number of people waiting are cataract extraction (3,564), knee replacement (1,274) and hip replacement (783). Oldfield said the progress comes down to the health authority's ability to make a plan and stick to it. "There's no magic," she said. "It's focus and discipline to do it." Although the health authority announced in 2023 a premium for doctors willing to work outside traditional hours in order to cut into the backlog, Oldfield said the biggest factor in making progress has been getting staffing levels back to where they needed to be coming out of the COVID-19 pandemic. "We did lose a lot of staff. Not just because of COVID, but people — they burn out, they age out, they retire. So we've been through a period of resurgence." Oldfield said she would like to see more surgeries happening during off-hours, but there needs to be a certain level of staffing to be able to make that work and take full advantage of available operating room time and equipment. "When we have assets, you want to use your assets," she said. "And when they sit idle, that's not a good thing. So we still have lots of time across the province that these could be used."
